Middle Meningeal Artery Embolization for the Treatment of Subdural Hematomas With TRUFILL® n-BCA

NCT ID: NCT04816591

Last Updated: 2025-11-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

376 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-05-27

Study Completion Date

2025-03-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a prospective, multi-center, open-label, randomized controlled study in which subjects can receive standard of care (SOC) alone or SOC and TRUFILL n-BCA MMA embolization for the treatment of chronic subdural hematomas (cSDH).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a prospective, multi-center, open-label, randomized controlled study in which up to 376 subjects will be randomized to receive standard of care (SOC) alone or SOC and TRUFILL n-BCA MMA embolization for the treatment of cSDH.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Subdural Hematoma

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Chronic Subdural Hematoma, MMA Embolization

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Experimental: Interventional Cohort: Treatment Arm

Standard of Care Surgery + Embolization

Group Type EXPERIMENTAL

Experimental: Interventional Cohort: TRUFILL n-Butyl Cyanoacrylate (n-BCA) Liquid Embolic System

Intervention Type DEVICE

Standard of Care Surgery + Embolization

Standard of Care Surgery Only

Standard of Care Surgery Only

Group Type ACTIVE_COMPARATOR

Standard of Care Surgery

Intervention Type OTHER

Standard of Care Surgery Only

Interventional Cohort: Treatment Arm

Standard of Care Medical Management + Embolization

Group Type EXPERIMENTAL

Experimental: Interventional Cohort: TRUFILL n-BCA Liquid Embolic System

Intervention Type DEVICE

Standard of Care Medical Management + Embolization

Standard of Care Medical Management Only

Standard of Care medical management only.

Group Type ACTIVE_COMPARATOR

Standard of Care Medical Management

Intervention Type OTHER

Standard of Care Medical Management Only

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Experimental: Interventional Cohort: TRUFILL n-Butyl Cyanoacrylate (n-BCA) Liquid Embolic System

Standard of Care Surgery + Embolization

Intervention Type DEVICE

Standard of Care Surgery

Standard of Care Surgery Only

Intervention Type OTHER

Experimental: Interventional Cohort: TRUFILL n-BCA Liquid Embolic System

Standard of Care Medical Management + Embolization

Intervention Type DEVICE

Standard of Care Medical Management

Standard of Care Medical Management Only

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Pre-randomization mRS \</= 3
* Confirmed diagnosis of chronic subdural hematoma
* Completed informed consent

Exclusion Criteria

* Acute subdural hematoma
* Prior treatment of target subdural hematoma
* Markwalder assessment \>/= 3
* Glasgow Coma Scale \< 9
* Presumed microbial superinfection
* CT or MRI evidence of intracranial tumor or mass lesion
* Life expectancy \< 1 year
* Women who are pregnant, lactating, or who are of childbearing age and plan on becoming pregnant during the study
* Current involvement in another clinical trial that may confound study endpoints
Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Cerenovus, Part of DePuy Synthes Products, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Christopher Kellner, MD

Role: PRINCIPAL_INVESTIGATOR

MOUNT SINAI HOSPITAL

Ansaar Rai, MD

Role: PRINCIPAL_INVESTIGATOR

West Virginia University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Alabama at Birmingham

Birmingham, Alabama, United States

Site Status

Carondelet St Joseph's Hospital

Tucson, Arizona, United States

Site Status

John Muir Physician Network Clinical Research Center

Walnut Creek, California, United States

Site Status

Swedish Medical Center

Englewood, Colorado, United States

Site Status

Hartford Hospital

Hartford, Connecticut, United States

Site Status

Yale University

New Haven, Connecticut, United States

Site Status

George Washington University

Washington D.C., District of Columbia, United States

Site Status

Baptist Medical Center

Jacksonville, Florida, United States

Site Status

University of Miami - Jackson Memorial Hospital

Miami, Florida, United States

Site Status

Advent Health Orlando

Orlando, Florida, United States

Site Status

Piedmont Hospital

Atlanta, Georgia, United States

Site Status

Wellstar Health System

Marietta, Georgia, United States

Site Status

Memorial Health University Health Center

Savannah, Georgia, United States

Site Status

University of Maryland

Baltimore, Maryland, United States

Site Status

Lahey Hospital & Medical Center

Burlington, Massachusetts, United States

Site Status

University of Minnesota

Minneapolis, Minnesota, United States

Site Status

Mount Sinai Hospital

New York, New York, United States

Site Status

Westchester Medical Center

Valhalla, New York, United States

Site Status

Duke University Medical Center

Durham, North Carolina, United States

Site Status

University of Cincinnati

Cincinnati, Ohio, United States

Site Status

Ohio Health

Columbus, Ohio, United States

Site Status

Mercy Health St Vincent Medical Center

Toledo, Ohio, United States

Site Status

Oregon Health and Science University

Portland, Oregon, United States

Site Status

Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania, United States

Site Status

Allegheny General Hospital of Research

Pittsburgh, Pennsylvania, United States

Site Status

Semmes Murphey Foundation

Memphis, Tennessee, United States

Site Status

Vanderbilt University Medical Center

Nashville, Tennessee, United States

Site Status

Texas Stroke Institute

Plano, Texas, United States

Site Status

University of Utah

Salt Lake City, Utah, United States

Site Status

University of Virginia School of Medicine

Charlottesville, Virginia, United States

Site Status

West Virginia Hospital

Morgantown, West Virginia, United States

Site Status

Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School

Nanjing, , China

Site Status

Renji Hospital, Shanghai Jiaotong University School of Medicine

Shanghai, , China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States China

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CNV_2020_01

Identifier Type: -

Identifier Source: org_study_id